eukaryotic translation initiation factor 4E binding protein 1Genealiases: 4E-BP1 · 4EBP1 · BP-1 · PHAS-I
Q-omics provides the consensus-scored EIF4EBP1 profile across patient tissues and cancer cell-line models. EIF4EBP1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, EIF4EBP1 is differentially expressed in 17, with the highest sampling consensus in KIRC. Additionally, EIF4EBP1 RNA expression shows 19,544 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where EIF4EBP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EIF4EBP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EIF4EBP1 survival associations across molecular data types. EIF4EBP1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EIF4EBP1 RNA expression–survival associations across cancer types. High EIF4EBP1 expression shows unfavorable associations in KIRC, ACC, MESO, KIRP, KICH and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for EIF4EBP1 RNA expression.
This table summarizes EIF4EBP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for EIF4EBP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EIF4EBP1 shows higher tumor expression in KIRC, HNSC, COAD, BLCA, KIRP and LUSC. The KIRC box plot shows higher EIF4EBP1 RNA expression in tumor versus normal tissue (log2 FC = +2.203, t-test p < 0.001).
This table shows molecular features associated with EIF4EBP1 in patient tissues and cancer cell lines. In patient samples, EIF4EBP1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, EIF4EBP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
